A5067110431- Monoclonal and Polyclonal Antibodies Research
- Complement system in diseases
- Chronic Lymphocytic Leukemia Research
- Systemic Lupus Erythematosus Research
- Lymphoma Diagnosis and Treatment
- Glycosylation and Glycoproteins Research
- Nanoparticle-Based Drug Delivery
- Platelet Disorders and Treatments
- Immunotherapy and Immune Responses
- Blood groups and transfusion
- Rheumatoid Arthritis Research and Therapies
- Acute Lymphoblastic Leukemia research
- Orthopedic Infections and Treatments
- RNA Interference and Gene Delivery
- Renal Diseases and Glomerulopathies
- Advanced biosensing and bioanalysis techniques
- HER2/EGFR in Cancer Research
- Blood disorders and treatments
- Cell Adhesion Molecules Research
- Immune Cell Function and Interaction
- Reproductive System and Pregnancy
- CAR-T cell therapy research
- Immunodeficiency and Autoimmune Disorders
- Toxin Mechanisms and Immunotoxins
- Multiple Myeloma Research and Treatments
University of Trieste
2016-2025
Istituti di Ricovero e Cura a Carattere Scientifico
2005-2020
Centro di Riferimento Oncologico
2020
Johannes Gutenberg University Mainz
2008
Bracco (Italy)
2008
University of Palermo
2008
IRCCS Istituto Auxologico Italiano
2005
University of Milan
2005
Università degli Studi del Piemonte Orientale “Amedeo Avogadro”
2005
Abstract An in vivo model of human CD20+ B-lymphoma was established severe combined immunodeficiency mice to test the ability neutralizing miniantibodies CD55 and CD59 (MB55 MB59) enhance therapeutic effect rituximab. The contained single-chain fragment variables hinge-CH2-CH3 domains IgG1. LCL2 cells were selected for study among six cell lines their high susceptibility rituximab-dependent complement-mediated killing enhanced by MB55 MB59. injected i.p. primarily colonized liver spleen,...
Increased levels of circulating complement activation products have been reported in COVID-19 patients, but only limited information is available on involvement at the tissue level. The mechanisms and pathways local remain unclear. aim this study was to investigate deposition components lungs, kidneys, liver patients with determine pathway/s activation. We performed immunofluorescence analyses autopsy specimens kidney, from 12 who died acute respiratory failure. Snap-frozen samples embedded...
Gene variants in the alternative pathway of complement system strongly associate with atypical hemolytic uremic syndrome (aHUS), presumably by predisposing to increased activation within kidney. Complement factor H (CFH) is major regulator through pathway. Factor H-deficient mice transgenically expressing a mutant CFH protein (Cfh(-/-).FHΔ16-20) that functionally mimics mutations reported aHUS patients spontaneously develop thrombotic microangiopathy. To investigate role C5 this model, we...
Antiphospholipid syndrome (APS) is an acquired autoimmune disease characterized by thromboembolic events, pregnancy morbidity, and the presence of antiphospholipid (aPL) antibodies. There sound evidence that aPL act as pathogenic autoantibodies being responsible for vascular clots miscarriages. However, exact mechanisms involved in clinical manifestations are still a matter investigation. In particular, while thrombosis apparently not associated with inflammation, pathogenesis miscarriages...
Expression of the complement-regulatory proteins (CRP) CD46, CD55 and CD59 represents a strategy used by tumor cells to evade complement-dependent cell cytoxicity stimulated monoclonal antibodies.We have isolated two single-chain variable fragments (scFv) from human phage-display library these scFv we produced miniantibodies (MB), MB-55 (against CD55) MB-59 CD59), containing hinge-CH2-CH3 domains IgG1.The specificity MB for corresponding CRP was assessed ELISA using purified CD59.MB-55...
Clinical studies have reported different diagnostic/predictive values of antibodies to domain 1 or 4/5 β2glycoproteinI in terms risk thrombosis and pregnancy complications patients with antiphospholipid syndrome. To obtain direct evidence for the pathogenic role anti-domain antibodies, we analyzed vivo pro-coagulant effect two groups 5 sera IgG each reacting selectively lipopolysaccharide (LPS)-treated rats. Antibody-induced thrombus formation mesenteric vessels was followed by intravital...
Drug delivery strategies using chitosan nanobubbles (CS-NBs) could be used to reduce drug side effects and improve outcomes in hepatocellular carcinoma (HCC) treatment. To enhance their action, a targeting agent, such as the humanized anti-GPC3 antibody GC33 (condrituzumab), attached surface. Here, we investigated use of idarubicin-loaded CS-NBs for HCC treatment GC33-derived minibody (that named 4A1) CS-NB delivery. Various formulations were prepared with or without 4A1 conjugation...
Introduction The functionalization of nanoparticles (NPs) with an antiCD19 targeting mechanism represents a promising approach for the selective delivery drugs and nucleic acids into normal tumor B cells. This strategy has advantage minimizing off-target effects by restricting gene to desired cell population. However, nanoplatform must guarantee both local production protein safety treatment allow effective therapy reduced systemic toxicity. Methods In order ensure acids, we developed...
Anti-phospholipid syndrome (APS) is a systemic autoimmune disease characterized by thrombotic vascular occlusion and maternal morbidity. Anti-coagulants remain pivotal drugs for the management of APS, but significant proportion patients do not benefit from long-term anti-coagulation may require an alternative therapy to prevent antibody deposition thrombosis. We have developed therapeutic approach based on use safe polymeric nanoparticles that selectively target beta2-glycoprotein I (β2GPI)...
Abstract Objectives The Certified Reference Material (CRM) ERM ® -DA477/IFCC is a new polyclonal IgG anti-beta2-glycoprotein I (anti-β2GPI) material for the harmonization of laboratory diagnosis antiphospholipid syndrome (APS). We evaluated CRM’s ability to represent heterogeneity APS patient anti-β2GPI antibodies and calibrate methods. Methods characterized CRM its reactivity against domain-1, using QUANTA Flash β2GPI-domain-1 assay, domains-4-5 β2GPI, single-domain-deleted β2GPI molecules...